Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia

about

"De-escalation" strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany.

P2860

Q47102441-319063B3-3A65-48BB-AE3B-7615DFAB3E7A

P2860

Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia

Item

http://www.wikidata.org/entity/Q37229198

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacoeconomic Analysis of M ...... In the Treatment of Candidemia

@en

Pharmacoeconomic Analysis of Micafungin

@nl

type

Item

label

Pharmacoeconomic Analysis of M ...... In the Treatment of Candidemia

@en

Pharmacoeconomic Analysis of Micafungin

@nl

prefLabel

Pharmacoeconomic Analysis of M ...... In the Treatment of Candidemia

@en

Pharmacoeconomic Analysis of Micafungin

@nl

P1476

Pharmacoeconomic Analysis of M ...... In the Treatment of Candidemia

@en

P2093

Kwaku Marfo

http://www.w3.org/2001/XMLSchema#string

Yi Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Attributable mortality of nosocomial candidemia, revisited.

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

P304

196-199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19561860

http://www.w3.org/2001/XMLSchema#string

P932

2697091

http://www.w3.org/2001/XMLSchema#string

Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia

about

P2860

P2860

Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P932